Top

Journal of Diabetes & Metabolic Disorders

18-04-2024 | Diabetic Retinopathy | Research article

MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy

Authors: Bruno Rafael Virginio de Sousa, Alexandre Sérgio Silva, Caroline Severo de Assis, Tainá Gomes Diniz, Marina Gonçalves Monteiro Viturino, Isabella Wanderley de Queiroga Evangelista, Luiz Henrique Agra Cavalcante-Silva, Tatjana Souza Lima Keesen, Naila Francis Paulo de Oliveira, Darlene Camati Persuhn

Published in: Journal of Diabetes & Metabolic Disorders

Abstract

Purpose

To investigate the potential relation between methylation of miR-9-3 and stages of diabetic retinopathy (DR). Additionally, we explored whether miR-9-3 methylation impacts the serum levels of Vascular Endothelial Growth Factor (VEGF).

Methods

A cross-sectional study was conducted with 170 participants with type 2 diabetes, including a control group (n = 64) and a diabetes retinopathy group (n = 106), which was further divided into NPDR (n = 58) and PDR (n = 48) subgroups. Epidemiological, clinical, anthropometric, biochemical ELISA assay were analysed. DNA extracted from leukocytes was used to profile miR-9-3 methylation using PCR-MSP.

Results

MiR-9-3 hypermethylated profile was higher in the DR group (p < 0.001) and PDR subgroup compared to DM2 control group (p < 0.001). The hypermethylated profile in the PDR subgroup was also higher compared to NPDR subgroup (p < 0.001). There was no difference between DM2 control and NPDR group (p = 0.234). Logistic regression showed that miR-9-3 hypermethylation increases the odds of presenting DR (OR: 2.826; p = 0.002) and PDR (OR: 5.472; p < 0.001). In addition, hypermethylation of miR-9-3 in the DR and NPDR subgroup was associated with higher serum VEGF-A levels (p = 0.012 and p = 0.025, respectively).

Conclusion

The methylation profile of the miR-9-3 promoter increases the risk of developing PDR. Higher levels of VEGF-A are associated with miR-9-3 hypermethylated profile in patients in the DR and NPDR stages.

Available only for authorised users

Khalil H. Diabetes microvascular complications-A clinical update. Diabetes Metab Syndr Clin Res Rev. 2017;11:S133–9. https://doi.org/10.1016/j.dsx.2016.12.022.CrossRef

Steinmetz JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to Sight: an analysis for the global burden of Disease Study. Lancet Glob Heal. 2021;9(2):e144–60. https://doi.org/10.1016/S2214-109X(20)30489-7.CrossRef

Ghamdi AH, Al. Clinical predictors of Diabetic Retinopathy Progression; a systematic review. Curr Diabetes Rev. 2020;16(3):242–7. https://doi.org/10.2174/1573399815666190215120435.CrossRefPubMed

Shiferaw WS, Akalu TY, Desta M, Kassie AM, Petrucka PM, Assefa HK, et al. Glycated hemoglobin A1C level and the risk of diabetic retinopathy in Africa: a systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(6):1941–9. https://doi.org/10.1016/j.dsx.2020.10.003.CrossRef

Liu Y, Li J, Ma J, Tong N. The threshold of the severity of Diabetic Retinopathy below which intensive glycemic control is Beneficial in Diabetic patients: estimation using data from large randomized clinical trials. J Diabetes Res. 2020;2020:1–6. https://doi.org/10.1155/2020/8765139.CrossRef

Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Prim. 2016;2(1):16012. https://doi.org/10.1038/nrdp.2016.12.CrossRefPubMed

Voigt M, Schmidt S, Lehmann T, Köhler B, Kloos C, Voigt U, et al. Prevalence and progression rate of Diabetic Retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. Exp Clin Endocrinol Diabetes. 2018;28(09):570–6. https://doi.org/10.1055/s-0043-120570.CrossRef

Gange WS, Lopez J, Xu BY, Lung K, Seabury SA, Toy BC. Incidence of proliferative Diabetic Retinopathy and other Neovascular sequelae at 5 years following diagnosis of type 2 diabetes. Diabetes Care. 2021;44(11):2518–26. https://doi.org/10.2337/dc21-0228.CrossRefPubMedPubMedCentral

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. https://doi.org/10.1038/nrg1379.CrossRefPubMed

10.

Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. Metabolism. 2022;126:154920. https://doi.org/10.1016/j.metabol.2021.154920.CrossRefPubMed

11.

Smit-McBride Z, Nguyen AT, Yu AK, Modjtahedi SP, Hunter AA, Rashid S, et al. Unique molecular signatures of microRNAs in ocular fluids and plasma in diabetic retinopathy. PLoS ONE. 2020;15(7):e0235541. https://doi.org/10.1371/journal.pone.0235541.CrossRefPubMedPubMedCentral

12.

Hildebrandt MAT, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29:5724–8. https://doi.org/10.1038/onc.2010.305.CrossRefPubMed

13.

Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem. 2006;281(37):26932–42. https://doi.org/10.1074/jbc.M601225200.CrossRefPubMed

14.

Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β-islets. FEBS J. 2011;278(7):1167–74. https://doi.org/10.1111/j.1742-4658.2011.08042.x.CrossRefPubMed

15.

Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol. 2006;4:210–20. https://doi.org/10.1371/journal.pbio.0040031.CrossRef

16.

Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, et al. Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005;2:105–17. https://doi.org/10.1016/j.cmet.2005.07.001.CrossRefPubMed

17.

Hu D, Wang Y, Zhang H, Kong D. Identification of miR-9 as a negative factor of insulin secretion from beta cells. J Physiol Biochem. 2018;74(2):291–9. https://doi.org/10.1007/s13105-018-0615-3.CrossRefPubMed

18.

Ostenson C-G, Gaisano H, Sheu L, Tibell A, Bartfai T. Impaired gene and Protein Expression of Exocytotic Soluble N -Ethylmaleimide Attachment Protein Receptor Complex Proteins in pancreatic islets of type 2 Diabetic patients. Diabetes. 2006;55:435–40. https://doi.org/10.2337/diabetes.55.02.06.db04-1575.CrossRefPubMed

19.

Dos Santos Nunes MK, Silva AS, Evangelista IWQ, Filho JM, Gomes CNAP, do Nascimento RAF, et al. Analysis of the DNA methylation profiles of miR-9-3, miR-34a, and miR-137 promoters in patients with diabetic retinopathy and nephropathy. J Diabetes Complications. 2018;32(6):593–601. https://doi.org/10.1016/j.jdiacomp.2018.03.013.CrossRefPubMed

20.

De Assis CS, Silva AS, dos Santos Nunes MK, Filho JM, do Nascimento RAF, Gomes CNAP, et al. Methylation Profile of Mir-9-1 and miR-9-1/-9-3 as potential biomarkers of Diabetic Retinopathy. Curr Diabetes Rev. 2021;17(6). https://doi.org/10.2174/1573399817666210101104326.

21.

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48(1):61–9. https://doi.org/10.1007/s00592-010-0226-0.CrossRefPubMed

22.

Motawae TM, Ismail MF, Shabayek MI, Seleem MM. MicroRNAs 9 and 370 Association with Biochemical Markers in T2D and CAD Complication of T2D. Ray RB, ed. PloS One. 2015;10(5):e0126957. https://doi.org/10.1371/journal.pone.0126957.

23.

Wang J, Chen S, Jiang F, You C, Mao C, Yu J, et al. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative Diabetic Retinopathy after Vitrectomy. PLoS ONE. 2014;9(10):e110531. https://doi.org/10.1371/journal.pone.0110531.CrossRefPubMedPubMedCentral

24.

Zhang D, Lv FL, Wang GH. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci. 2018;22:5071–6. https://doi.org/10.26355/eurrev_201808_15699.CrossRefPubMed

25.

Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Mech Angiogenes. 2005;94209–31. https://doi.org/10.1007/3-7643-7311-3_15.

26.

Xiao Y, Guo S, Zhang Y, Bian Z, Jia L, Hu Y, et al. Diabetic nephropathy: serum miR-9 confers a poor prognosis in and is associated with level changes of vascular endothelial growth factor and pigment epithelium-derived factor. Biotechnol Lett. 2017;39(10):1583–90. https://doi.org/10.1007/s10529-017-2390-6.CrossRefPubMed

27.

Kim BG, Gao MQ, Kang S, Choi YP, Lee JH, Kim JE, et al. Mechanical compression induces VEGFA overexpression in breast cancer via DNMT3A-dependent miR-9 downregulation. Cell Death Dis. 2017;8(3):e2646–2646. https://doi.org/10.1038/cddis.2017.73.CrossRefPubMedPubMedCentral

28.

Madelaine R, Sloan SA, Huber N, Notwell JH, Leung LC, Skariah G, et al. MicroRNA-9 couples brain neurogenesis and angiogenesis. Cell Rep. 2017;20:1533–42. https://doi.org/10.1016/j.celrep.2017.07.051.CrossRefPubMedPubMedCentral

29.

Liu WL. MicroRNA-9 inhibits retinal neovascularization in rats with diabetic retinopathy by targeting vascular endothelial growth factor A. J Cell Biochem. 2019;120(5):8032–43. https://doi.org/10.1002/jcb.28081.CrossRefPubMed

30.

Brasil. Ministério Da Saúde. Secretaria De Vigilância em Saúde. VIGITEL Brasil 2006–2021. Vigilância De fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde; 2022.

31.

Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. Rationale, design, and methods of the action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol. 2007;99(12 SUPPL):S103–11. https://doi.org/10.1016/j.amjcard.2007.03.028.CrossRef

32.

Gangnon RE, Davis MD, Hubbard LD, Aiello LM, Chew EY, Ferris FL et al. A Severity Scale for Diabetic Macular Edema Developed from ETDRS Data. Invest Ophthalmol Vis Sci. 2008 1;49(11):5041–7. https://doi.org/10.1167/iovs.08-2231.

33.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of Low-Density Lipoprotein Cholesterol in plasma, without Use of the Preparative Ultracentrifuge. Clin Chem. 1972;18(6):499–502. https://doi.org/10.1093/clinchem/18.6.499.CrossRefPubMed

34.

Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci. 1996;93(18):9821–6. https://doi.org/10.1073/pnas.93.18.9821.CrossRefPubMedPubMedCentral

35.

Al-Rubeaan K, Abu El-Asrar AM, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, et al. Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. Acta Ophthalmol. 2015;93(2):e140–7. https://doi.org/10.1111/aos.12532.CrossRefPubMed

36.

Nittala MG, Keane PA, Zhang K, Sadda SR. Risk factors for proliferative Diabetic Retinopathy in a latino American Population. Retina. 2014;34:1594. https://doi.org/10.1097/IAE.0000000000000117.CrossRefPubMedPubMedCentral

37.

Al-Muhtaresh HA, Al-Kafaji G. Evaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes Mellitus. J Clin Me. 2018;7:12. https://doi.org/10.3390/jcm7020012.CrossRef

38.

Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, et al. Genome-wide miRNA expression profiling identifies mir-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res. 2012;18(6):1619–29. https://doi.org/10.1158/1078-0432.CCR-11-2450.CrossRefPubMed

39.

Gong Q, Su G. Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy. Biosci Rep. 2017;37:1–18. https://doi.org/10.1042/BSR20171157.CrossRef

40.

Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative Diabetic Retinopathy. Curr Diabetes Rev. 2006;2:71–98. https://doi.org/10.2174/157339906775473671.CrossRefPubMed

Title: MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy
Authors: Bruno Rafael Virginio de Sousa
Alexandre Sérgio Silva
Caroline Severo de Assis
Tainá Gomes Diniz
Marina Gonçalves Monteiro Viturino
Isabella Wanderley de Queiroga Evangelista
Luiz Henrique Agra Cavalcante-Silva
Tatjana Souza Lima Keesen
Naila Francis Paulo de Oliveira
Darlene Camati Persuhn
Publication date: 18-04-2024
Publisher: Springer International Publishing
Keywords: Diabetic Retinopathy
Diabetic Retinopathy
Epigenetics
Published in: Journal of Diabetes & Metabolic Disorders
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-024-01411-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials